Cargando…

Neuroprotective Effect of SGLT2 Inhibitors

Patients with diabetes are at higher risk of cardiovascular diseases and cognitive impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Sotagliflozin) are newer hypoglycemic agents with many pleiotropic effects. In this review, we discuss their neuroprotective po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pawlos, Agnieszka, Broncel, Marlena, Woźniak, Ewelina, Gorzelak-Pabiś, Paulina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659196/ https://www.ncbi.nlm.nih.gov/pubmed/34885795 http://dx.doi.org/10.3390/molecules26237213

Ejemplares similares

SGLT2 Inhibitors May Restore Endothelial Barrier Interrupted by 25-Hydroxycholesterol
por: Pawlos, Agnieszka, et al.
Publicado: (2023)

COVID-19: Direct and Indirect Mechanisms of Statins
por: Pawlos, Agnieszka, et al.
Publicado: (2021)

Cardiovascular risk and response to lipid lowering therapy in patients with HIV infection according to different recommendations
por: Pawlos, Agnieszka, et al.
Publicado: (2020)

Severe COVID-19 classified by simple covid risk index is associated with higher levels of advanced oxidation protein products and 8-hydroxy 2 deoxyguanosine
por: Satała, Joanna, et al.
Publicado: (2023)

Elevated Lp(a) and course of COVID-19: Is there a relationship?
por: Pawlos, Agnieszka, et al.
Publicado: (2022)

The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells
por: Woźniak, Ewelina, et al.
Publicado: (2023)

The Protective Effect of Dabigatran and Rivaroxaban on DNA Oxidative Changes in a Model of Vascular Endothelial Damage with Oxidized Cholesterol
por: Woźniak, Ewelina, et al.
Publicado: (2020)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Euthyroid Sick Syndrome as a Prognostic Indicator of COVID-19 Pulmonary Involvement, Associated With Poorer Disease Prognosis and Increased Mortality
por: Świstek, Magdalena, et al.
Publicado: (2022)

Increased plasma concentrations of interleukin 35 in patients with coronary artery disease
por: Gorzelak-Pabiś, Paulina, et al.
Publicado: (2016)

Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials
por: Broncel, Marlena, et al.
Publicado: (2015)

The effect of 7-ketocholesterol and 25-hydroxycholesterol on the integrity of the human aortic endothelial and intestinal epithelial barriers
por: Chalubinski, Maciej, et al.
Publicado: (2013)

Comprehensive insight into immune regulatory mechanisms and vascular wall determinants of atherogenesis – emerging perspectives of immunomodulation
por: Chalubinski, Maciej, et al.
Publicado: (2013)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
por: Szekeres, Zsolt, et al.
Publicado: (2021)

Direct cardiac effects of SGLT2 inhibitors
por: Chen, Sha, et al.
Publicado: (2022)

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
por: Kowalska, Klaudia, et al.
Publicado: (2022)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022)

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
por: Garofalo, Carlo, et al.
Publicado: (2019)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
por: Kluger, Aaron Y., et al.
Publicado: (2019)

The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
por: Koutentakis, Michail, et al.
Publicado: (2023)

Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease—Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
por: Lin, Kai-Jung, et al.
Publicado: (2021)

BCG and SARS-CoV-2—What Have We Learned?
por: Kulesza, Jakub, et al.
Publicado: (2022)

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
por: Tentolouris, Anastasios, et al.
Publicado: (2019)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

SGLT2 Inhibitors as Potential Anticancer Agents
por: Basak, Debasish, et al.
Publicado: (2023)

The Role of SGLT2 Inhibitors in Vascular Aging
por: Liu, Le, et al.
Publicado: (2021)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
por: Liu, Shuangbo, et al.
Publicado: (2019)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
por: Hou, Yi-Chou, et al.
Publicado: (2020)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
por: Salvatore, Teresa, et al.
Publicado: (2022)

SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
por: Chan, Jonathan C. H., et al.
Publicado: (2023)

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
por: Saisho, Yoshifumi
Publicado: (2020)

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
por: Palmiero, Giuseppe, et al.
Publicado: (2021)

Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
por: Yaribeygi, Habib, et al.
Publicado: (2022)

Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
por: Schönberger, Ema, et al.
Publicado: (2023)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
por: Sha, Wenjun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gr6rk5dum598ton9hjvs77380p